North American capsule endoscopy market seeks minimally invasive procedures
Within the North American region, Canada is anticipated to see the strongest growth at 7% CAGR, followed by Mexico with 6.2% and the US with 6.1%.
The US makes up the largest portion of the North American capsule endoscopy market. Market growth in North America is largely driven by the increasing population, the rising incidence of gastrointestinal diseases and a growing preference among patients and providers for minimally invasive procedures. Technological advancements aimed at enhancing imaging quality and the control capabilities of these capsule devices are further accelerating market adoption.
Capsule endoscopy involves the utilisation of small medical devices, typically weighing between 1.9 grams and 4 grams. These capsules are equipped with a battery, light source, camera and transmitter. Once ingested by the patient, the capsule travels through the digestive tract, transmitting detailed images from the oesophagus, stomach and small bowel to an external receiver.
The market is growing as new applications for capsule endoscopy emerge, replacing traditional endoscopic procedures. Medtronic holds a dominant position in North America, with 89.4% of market share. Continued innovation and expanded indications for capsule endoscopy are expected to sustain robust market growth throughout the forecast period.
"North American capsule endoscopy market seeks minimally invasive procedures" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
30 minutes ago
- Yahoo
Public Health Workers Criticize RFK Jr. After CDC Shooting
HHS Secretary Robert F. Kennedy Jr. speaks at an event at the USDA Whitten Building on Aug. 4, 2025. Credit - Tom Williams—CQ-Roll Call, Inc/Getty Images More than 750 public health workers sent a letter to Health Secretary Robert F. Kennedy Jr. on Wednesday, urging him to 'stop spreading inaccurate health information' and guarantee employees' safety, in the wake of a shooting at the headquarters of the Centers for Disease Control and Prevention (CDC) earlier this month. The letter—signed by both named and anonymous current and former staffers at the U.S. Department of Health and Human Services (HHS), CDC, and National Institutes of Health who noted they signed the letter in their 'own personal capacities'—said the attack on the CDC's headquarters in Atlanta on Aug. 8 'was not random.' 'The attack came amid growing mistrust in public institutions, driven by politicized rhetoric that has turned public health professionals from trusted experts into targets of villainization—and now, violence,' public health workers said in the letter, which was also addressed to members of Congress. 'CDC is a public health leader in America's defense against health threats at home and abroad. When a federal health agency is under attack, America's health is under attack. When the federal workforce is not safe, America is not safe.' The public health workers went on to accuse Kennedy, a prominent vaccine skeptic, of being 'complicit in dismantling America's public health infrastructure and endangering the nation's health by repeatedly spreading inaccurate health information.' They cited several statements and actions that Kennedy has made in recent months, pointing to his claim that mRNA vaccines 'fail to protect effectively' against upper respiratory infections such as COVID-19—despite years of research showing that the shots are both safe and effective—and his announcement that HHS would be winding down mRNA vaccine development. They also condemned his decision to remove all the experts from a critical vaccine advisory committee. And they said some of Kennedy's past comments—such as claiming that there is a 'cesspool of corruption at CDC'—were 'sowing public mistrust' in the health agency. Read more: Trump Administration to Wind Down mRNA Vaccine Development The public health workers expressed their wish to honor police officer David Rose, who was killed while responding to the attack on the CDC headquarters in August. HHS said in a statement to TIME that Kennedy 'is standing firmly with CDC employees—both on the ground and across every center—ensuring their safety and well-being remain a top priority.' The agency added that, after the shooting earlier this month, Kennedy traveled to Atlanta and called the CDC 'a shining star' among the world's health agencies. 'For the first time in its 70-year history, the mission of HHS is truly resonating with the American people—driven by President Trump and Secretary Kennedy's bold commitment to Make America Healthy Again,' HHS said. 'Any attempt to conflate widely supported public health reforms with the violence of a suicidal mass shooter is an attempt to politicize a tragedy.' Law enforcement officials said they found evidence that the suspect in the August shooting, who they identified as Patrick Joseph White of Georgia, blamed the COVID-19 vaccine for his health ailments. White was found dead at the scene, and authorities later said that he died of a self-inflicted gunshot wound. CDC Director Susan Monarez noted the dangers posed by misinformation in a staff meeting in the wake of the attack. 'We know that misinformation can be dangerous,' she said, according to NBC News. 'Not only to health, but to those that trust us and those we want to trust. We need to rebuild the trust together.' The day after the shooting, Kennedy expressed his condolences to Rose's family in a post on X. 'We know how shaken our public health colleagues feel today. No one should face violence while working to protect the health of others,' he said. 'We are actively supporting CDC staff on the ground and across the agency. Public health workers show up every day with purpose—even in moments of grief and uncertainty. We honor their service. We stand with them. And we remain united in our mission to protect and improve the health of every American.' Kennedy was one of President Donald Trump's most controversial Cabinet nominees, and faced heated questioning by Senators during his confirmation hearings. He has drawn outrage from the medical establishment in the past for spreading disinformation, including repeating the debunked claim that vaccines cause autism. In their letter, public health workers claimed Kennedy's 'dangerous and deceitful statements and actions have contributed to the harassment and violence experienced by CDC staff.' They implored him to take three steps by Sept. 2 to 'uphold his pledge to safeguard the health of the American public,' including asking him to 'stop spreading inaccurate health information,' particularly regarding vaccines, infectious disease transmission, and the country's public health institutions. They also urged him to affirm the scientific integrity of the CDC and guarantee the safety of HHS employees, such as through emergency procedures and alerts. 'The deliberate destruction of trust in America's public health workforce puts lives at risk,' they wrote in the letter. 'We urge you to act in the best interest of the American people—your friends, your families, and yourselves.' Contact us at letters@
Yahoo
an hour ago
- Yahoo
FDA Pushes Back Eylea HD Review; Regeneron Still Gains
This article first appeared on GuruFocus. Regeneron (NASDAQ:REGN) picked up gains Tuesday after announcing that the FDA pushed back decision timelines for two key reviews of its high-dose Eylea (aflibercept) injection. The new action dates fall in the fourth quarter of 2025, covering a prior-approval supplement for a prefilled syringe and a label expansion filing to treat macular edema after retinal vein occlusion (RVO). Warning! GuruFocus has detected 3 Warning Signs with REGN. The company is also seeking to expand Eylea HD's dosing schedule to every 4 weeks across approved uses a shift from the current 816 week regimen for patients with wet AMD and diabetic macular edema. The extension stems from additional information submitted after an FDA inspection at Catalent Indiana LLC, the third-party manufacturer recently acquired by Novo Nordisk (NVO). The FDA classified the new submission as a major amendment, automatically extending review timelines. Novo Nordisk provided a detailed response earlier this month in an effort to address the agency's concerns. For now, Eylea HD remains available via vial administration, but the delay tempers near-term expectations around label expansion and convenience upgrades. Still, investors seem encouraged, with shares moving higher on confidence the regulator will complete its review later this year. Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
an hour ago
- Yahoo
Numinus Wellness Inc. Announces Second Quarter Fiscal 2025 Results
All financial results are reported in Canadian dollars unless otherwise stated. Vancouver, British Columbia--(Newsfile Corp. - August 20, 2025) - Numinus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) (FSE: LR23) ("Numinus" or the "Company"), a mental health care company focused on innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, today announced its financial results for the three months ended February 28, 2025 ("Q2 2025"). Q2 2025 Performance Metrics For the quarter ended:Feb 28, 2025(Q2 2025) Feb 28, 2024(Q2 2024) % change Total Revenue $ 1,512,435$ 822,973 83.8%Cost of revenue1,007,691 365,446 175.7%Gross Profit (Loss) $ 504,744$ 457,527 10.3% Gross profit margin (loss)33.4% 55.6% -400 bpsOperating expenses and other items9,886,497 5,306,523 86.31%Loss and comprehensive loss($7,705,397 )($5,960,437 )n/a Balance Sheet and LiquidityNuminus ended the quarter with cash and cash equivalents of $705,631. Numinus' unaudited condensed consolidated interim financial statements for the three months ended February 28, 2025, and related management's discussion and analysis are available on Numinus' Investor Relations website at and under the Company's profile on SEDAR+ at These documents were prepared in accordance with IFRS. About NuminusNuminus Wellness Inc. (TSX: NUMI) (OTCQB: NUMIF) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model — including psychedelic research and clinic care — is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society. Learn more at and follow us on LinkedIn, Facebook, Twitter, and Instagram. SOURCE: Numinus Wellness Inc. Forward-Looking Statements This press release contains forward-looking statements within the meaning of applicable securities laws. All statements that are not historical facts, including, without limitation, statements regarding future estimates, plans, programs, forecasts, projections, objectives, assumptions, expectations or beliefs regarding future performance are "forward-looking statements". Forward-looking statements can be identified by the use of words such as "expects", "does not expect", "is expected", "believes", "intends", "anticipates", "does not anticipate", "believes" or variations of these words, expressions or statements, that certain actions, events or results "may", "could", "would", "might" or "will be" taken, will occur or will be realized. Such forward-looking statements involve risks, uncertainties and other known and unknown factors that could cause actual results, events or developments to differ materially from the results, events or developments expected and expressed or implied in such forward-looking statements. These risks and uncertainties include, but are not limited to, ability of Numinus to maintain or increase earnings; ability of Numinus to achieve or maintain profitability; results of changes to operations from a financial or business perspective; the effect of cost containment measures on Numinus business and financial position; changes to cash burn rate, expenses, corporate programs or priorities, or unanticipated costs affecting cash runway or the pathway to positive cashflow or profitability, interest in, uptake of and the ability to commercialize the Numinus Training; availability of subjects and trainers for experiential opportunities in practitioners training, if approved; dependence on obtaining and maintaining regulatory approvals, including the acquisition and renewal of federal, provincial, municipal, local or other licenses, and any inability to obtain all necessary government authorizations, licenses and permits to operate the Company's facilities; regulatory or policy changes such as changes in applicable laws and regulations, including federal, state and provincial legalization, if any, due to fluctuations in public opinion, industry perception of integrative mental health, including the use of psychedelic-assisted therapy, delays or inefficiencies or any other reason; any other factor or development likely to hamper the growth of the market; the Company's need for additional financing and the effects of financial market conditions and other factors on the availability of capital; competition, including that of more established and better funded competitors; the need to build and maintain alliances and partnerships, including with research and development companies, customers and suppliers; and other risk factors set forth in our annual information form dated July 25, 2025 and available on SEDAR+ at These factors should be carefully considered, and readers are cautioned not to place undue reliance on forward-looking statements. Despite the Company's efforts to identify the main risk factors that could cause actual measures, events or results to differ materially from those described in forward-looking statements, other risk factors may cause measures, events or developments to materially differ from those anticipated, estimated or intended. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in forward-looking statements. The Company does not undertake to revise forward-looking statements, even if new information becomes available as a result of future events, new facts or any other reason, except as required by applicable laws. For more information:Investor ContactCraig MacPhailinvest@ To view the source version of this press release, please visit Sign in to access your portfolio
